

Spring Group Meeting

San Francisco Specials

APRIL 30 - MAY 2, 2026



Gastrointestinal Committee

Gastrointestinal Committee

Leadership

Chair: Philip A. Philip, MD, PhD, FRCP
 Vice-Chair: Elena Gabriela Chiorean, MD, FASCO
 Executive Officer: Hagen Kennecke, MD, MHA
 Statisticians: Katherine A. Guthrie, PhD
 Sarah Colby, MS
 Sara Threlkel, BS

Scientific Leadership

Gastroesophageal: Syma Iqbal, MD
 Zev A. Wainberg, MD
 Pancreatic: Davendra P.S. Sohal, MD
 Andrew M. Lowy, MD (Surgical representative)
 Hepatobiliary: Anthony B. El-Khoueiry, MD
 Rachna T. Shroff, MD
 Syed A. Ahmad, MD (Surgical representative)
 Colon: Marwan G. Fakhri, MD
 Philip J. Gold, MD
 Sepideh Gholami, MD (Surgical representative)
 Neuroendocrine Tumors: Nageshwara Arvind Dasari, MD
 Aman Chauhan, MD
 Ano-Rectal: Lisa A. Kachnic, MD
 Hagen F. Kennecke, MD
 Imaging: Anthony F. Shields, MD, PhD
 Pathology: Mary Kay Washington, MD, PhD
 Radiation Oncology: Lisa A. Kachnic, MD
 Surgery: Stephen W. Behrman, MD
 Syed A. Ahmad, MD
 Flavio Rocha, MD
 Translational Medicine: Gabriel N. Duda, PhD, DMD
 Eric Collisson, MD
 HEARD: Rachel Safyan, MD
 Colmar Figueroa-Moseley, PhD, MPH

Designates

Cancer Control Liaisons: Jason A. Zell, DO (Prevention)
 Vincent Chung, MD (Palliative Care)
 Community Liaisons: Gary L. Buchsacher, MD, PhD (Medical Oncology)
 Mohamed E. Salem, MD (Medical Oncology)
 Flavio Rocha, MD (Surgical)
 David Horowitz, MD (Radiation Oncology)
 AYA Committee Liason: Christopher Cann, MD
 Veterans Affairs: Rangaswamy Govindarajan, MD
 Data Coordinators: Alex Rangel, BS
 Brian Zeller
 Christine Magner

Oncology Research Professionals: Samantha Elliott, CCRP
 Adriana Gamboa Guzman, BA
 Patient Advocate (Colon): Angela "Marielle" McLeod, MHA
 Patient Advocate (Pancreatic): TBD
 Pharmaceutical Science: Jane E. Rogers, PharmD
 Safae Chouraichi, PharmD
 Protocol Project Manager: Andrea Garcia
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Friday, May 1, 2026 4:30 p.m. - 6:30 p.m.
 Room: Garden Room (Atrium Lobby Level)

Agenda

1. Welcome
2. Announcements & Introductions Philip Philip
E. Gabriela Chiorean
3. HEARD Subcommittee Initiatives Rachel Safyan, Colmar Figueroa -
Moseley, Marielle McLeod
4. Molecular Testing for Pancreatic and Biliary Cancers and Clinical Trials Applications Harsh Singh
5. SWOG Led Active Trials
 - a. S1922 Michael Overman
 - b. S2001 Vincent Chung
 - c. S2104 Heloisa Soares/S. Ahmad
 - d. S2107 Van Morris
 - e. S2012 David Zhen/E. Gabriela Chiorean
 - f. S2303 Anwaar Saeed/Paul Oberstein
 - g. S2408 Jonathan Sham/Venu Pillarisetty
 - h. S2433 Rachael Safyan/E. Gabriela Chiorean
6. Gastroesophageal Syma Iqbal, Zev Wainberg
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans
7. Pancreatic Davendra Sohal, Andrew Lowy
 - a. Major recent clinical results
 - b. NCTN trials update
 - c. Future SWOG plans

Gastrointestinal Committee

- | | |
|---|--|
| 8. Colon | Marwan Fakh, Philip Gold,
Sepideh Gholami |
| <ul style="list-style-type: none"> a. Major recent clinical results b. NCTN trials update c. Future SWOG plans | |
| 9. Anal and Rectal | Hagen Kennecke, Lisa Kachnic |
| <ul style="list-style-type: none"> a. Major recent clinical results b. NCTN trials update c. Future SWOG plans | |
| 10. Hepatobiliary | Anthony El-Khoueiry
Rachna Shroff |
| <ul style="list-style-type: none"> a. Major recent clinical results b. NCTN trials update c. Future SWOG plans | |
| 11. Neuroendocrine | Arvind Dasari, Aman Chauhan |
| <ul style="list-style-type: none"> a. Major recent clinical results b. NCTN trials update c. Future SWOG plans | |
| 12. Discussion/Other Business | |
| 13. Adjourn | |

Gastroesophageal

Active Studies

- S2303**, "Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS \geq 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)." Dra. Saeed and Oberstein. Activated: 5/6/24
- A022102**, "Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma." SWOG Champion: Dr. Oberstein. Activated: 1/17/19.
- EA2174**, "A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma." SWOG Champion: Dr. Kelly. Activated: 1/17/19. Temporarily Closed to Accrual as of 12/29/22.
- EA2212**, "A Randomized Phase II Study of Perioperative Atezolizumab +/- Chemotherapy in Resectable MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer." SWOG Champion: Emerson Chen Temporarily Closed to Accrual as of 12/4/24

Closed Studies

- A021302**, "Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study." Activated by SWOG: 4/1/16. Closed to Accrual on 6/1/17. SWOG Champion: S. Iqbal.
- EA2183**, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)." Activated: 2/6/20. Closed to Accrual as of 5/23/25. SWOG Champion: D. Horowitz

Pancreatic

Active Studies

- S2408**, "A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula." Drs. J. Sham, V. Pillarisetty, and R. Krouse. Activated: 2/14/25
- S2433**, "Randomized Phase III Study of Second-Line Chemotherapy with or without Panitumumab for Locally Advanced or Metastatic KRAS Wild Type Pancreatic Adenocarcinoma." Drs. R. Safyan, E. Chiorean, and H. Singh. Activated: 12/26/25
- EA2192**, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation." SWOG Champions: E. Chiorean and P. Philip. Activated: 4/29/21.

Closed Studies

- S2001**, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or 2 Mutations." Drs. V. Chung, and M. Pishvaian. Activated: 12/4/20; Closed to Accrual as of 10/23/25
- EA2186**, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)." Activated: 6/18/20. Closed to Accrual as of 10/17/23. SWOG Champion: D. Zhen.
- RTOG-0848**, "Gemcitabine, with and without Erlotinib, Followed by a Second Randomization with and without Chemoradiation, as Adjuvant Treatment for Pancreatic Head Cancer: A Phase III RTOG/SWOG/NCIC/EORTC Study." Activated 11/7/09; Closed to accrual as of 1/18/19. SWOG Champion: P. Philip.

Gastrointestinal Committee

A021501, "Preoperative Extended Chemotherapy vs Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas." Activated: 12/1/16, Closed to accrual as of 5/6/19. SWOG Champion: S. Ahmad.

EA2161, "A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)." Activated: 2/1/17, Closed to Accrual as of 12/27/19

A022106, "A Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/ Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)." Activated: 12/1/23, Closed to Accrual as of 12/24/25. SWOG Champion: G. Botta

A021804, "A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma." Activated: 11/2/20. Closed to Accrual as of 6/2/25. SWOG Champion: C. Lopez.

A021806, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer." Activated: 7/1/20. Closed to accrual as of 1/5/26. SWOG Champion: S. Behrman

Neuroendocrine

Active Studies

S2104, "Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors." Activated: 10/14/21. Drs. Study Chairs: H. Soares, and S. Ahmad.

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)." Activated: 12/2/21. Drs. D. Zhen, E. Chiorean, E. Burgess, E. Swisher, and L. Byers.

Closed Studies

A021602, "Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced Neuroendocrine Tumors after Progression on Prior Therapy (CABINET)." Activated: 7/18/18. Closed to Accrual as of 9/8/23. SWOG Champion: J. Strosberg.

EA2142, "Randomized Phase II Study of Platinum and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas." Activation 11/6/15, Closed to Accrual as of 4/1/21. SWOG Champion: H. Soares

Hepatobiliary

Closed Studies

S1815, "A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers." Dr. R. Shroff. Activated: 12/3/18. Permanently Closed: 2/15/21.

NRG-GI003, "A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma." Activated: 6/21/17, Closed to accrual as of 1/14/26. SWOG Champion: Anthony El-Khoueiry.

EA2187, "A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma." Activated: 1/31/20. Permanently Closed: 3/22/23. SWOG Champion: Stacy Stein.

RTOG-1112, "Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma." L. Dawson. SWOG Champion: T. Mitin

EA2197, "Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial." Activated: 12/22/20, Closed to accrual as of 4/18/25. SWOG Champion: F. Rocha.

Colorectal

Active Studies

S1922, "Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma." Activated: 12/16/19. Dr. M. Overman

A022101, "A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)." Activated: 1/10/23. SWOG Champion: S. Gholami

EA2222, "A Randomized Phase III Study of Systemic Therapy with or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial." Activated: 10/19/23. SWOG Champion: Skye Mayo

NRG-GI008, "Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)." Activated: 3/10/22. SWOG Champions: P. Philip & C. Eng

Closed Studies

S2107, "Randomized Phase II Trial of Encorafenib and Cetuximab with or without Nivolumab for Patients with Microsatellite Stable, BRAFV600E

Gastrointestinal Committee

Metastatic Colorectal Cancer." Dr. Van Morris, MD. Activated: 6/6/22, Study closed to accrual 10/1/24

S1613, "A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification." Dr. Kanwal Raghav. Activated: 10/19/17. Step 3 permanently closed: 11/30/23

S0820, "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Dr. Jason Zell. Activated: 3/1/13. Permantley Closed: 6/30/23

A021502, "Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair." Activated: 9/12/17, Closed to Accrual as of 1/17/23. SWOG Champion: Chris Lieu

A021703, "Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)." Activated: 9/30/19, Closed to Accrual as of 12/15/22. SWOG Champion: Stacey Cohen.

E7208, "A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy." Activated 10/18/10, Closed to Accrual as of 7/7/17. SWOG Champion: H. Hochster.

NRG-GI004/ S1610, "Colorectal Cancer Metastatic dMMR/MSI-H Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/ Bevacizumab/Atezolizumab Combination versus Single Agent Atezolizumab in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer." Activated: 11/7/17, Closed to Accrual as of 9/2/25. SWOG Champion: M. Overman.

NRG-GI005, "Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)." Dr. A. Scott. Activated: 12/16/19, Closed to Accrual as of 2/12/24. SWOG Champion: A. Scott

Anal

Active Studies

EA2176, "Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer

Patients." Activated: 10/15/20, Closed to Accrual as of 9/23/24. SWOG Champion: Van Morris

Closed Studies

N1048, "A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision." Activated: 4/15/12. Accrual target: 1120 / Final accrual: 1194. SWOG Champion: Cathy Eng.

InterAACT EA2133, "An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-Fluorouracil Versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease." Activated: 2/15/16. Accrual target: 80 / Final accrual: 12. SWOG Champion: Van Morris.

NRG-GI002, "A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer." Activated: 10/12/16, Closed to Accrual as of 5/14/19. SWOG Champion: Lisa Kachnic

EA2165, "A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer." Activated: 4/13/18, Closed to Accrual as of 4/4/22. SWOG Champion: Van Morris

A022104, "The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer." Activated 11/9/22, Closed to Accrual as of 7/21/25. SWOG Champion: A. Dasari

EA2201, "A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma." Activated 5/13/21, Closed to Accrual as of 1/14/25. SWOG Champion: T. May Cho

EA2182, "A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)." Activated: 11/12/19, Closed to Accrual as of 10/30/24. SWOG Champion: James D. Murphy.

Gastrointestinal Committee

Publications

The publication papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

A021202 Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202). E Bergsland, S Geyer, T Asmis, S Behr, P Kumthekar, M Maitland, D Niedzwiecki, A Nixon, L Schwartz, J Strosberg, A Venook, E O'Reilly, J Meyerhardt. *J Clin Oncol*. 2025 Oct 10;43(29):3170-3183. doi: 10.1200/JCO-24-02644. Epub 2025 Sep 3. NIHMS2099573. <https://pubmed.ncbi.nlm.nih.gov/40902132/>

A021602 Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602). Jonathan R Strosberg, Tyler Zemla, Susan Geyer, Sydney Pulsipher, Fang-Shu Ou, Spencer Behr, Nitya Raj, Namrata Vijayvergia, Arvind Dasari, Eileen M O'Reilly, Jeffrey A Meyerhardt, Edward M Wolin, Thorvardur R Halfdanarson, Jennifer A Chan. *Endocr Relat Cancer*. 2026 Jan 24;33(1):e250415. doi: 10.1530/ERC-25-0415. Print 2026 Jan 1. <https://pubmed.ncbi.nlm.nih.gov/41524552/>

C/S80405 GABAergic signaling contributes to tumor cell invasion and poor overall survival in colorectal cancer. C Strelez, F Battaglin, R Perez, Y Yang, C Cherry, J Millstein, A Yoon, J Chylstek, E Canfield, B Haliday, C Shah, K Ghaffarian, S Soni, H Jiang, R Lau, A Schatz, Y Zhou, D Mulkerin, F Ou, A Venook, F Innocenti, J Neman, J Katz, H-J Lenz, S Mumenthaler. *Oncogene* 2025 Oct 44;3924-3938. doi: 10.1038/s41388-025-03546-2. Epub 2025 Aug 24. <https://pubmed.ncbi.nlm.nih.gov/40851030/>

C/S80405 Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance). F Battaglin, B O'Neil, S Stintzing, F Ou, T Zemla, D Niedzwiecki, F Innocenti, H Hochster, L von Weikersthal, T Decker, A Kiani, U Vehling-Kaiser, T Heintges, C Lerchenmuller, L Weiss, K Heinrich, R Goldberg, R Mayer, R Schilsky, C Blanke, A Venook, H-J Lenz, V Heinemann. *European Journal of Cancer* Sep 9;227:115694. <https://pubmed.ncbi.nlm.nih.gov/40803104/>

C/S80405/Others Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, Yoshiaki Nakamura, Simone Oldani, Francesca

Battaglin, Francesca Bergamo, Lisa Salvatore, Arndt Stahler, Carlotta Antoniotti, Kohei Shitara, Alan Venook, Eiji Oki, Kei Muro, Clara Ugolini, Junpei Soeda, Sara Lonardi, Filippo Pietrantonio, Heinz-Josef Lenz, Dominik Paul Modest, Takayuki Yoshino, Chiara Cremolini. *J Clin Oncol*. 2025 Oct 10;43(29):3184-3197. doi: 10.1200/JCO-25-01003. Epub 2025 Sep 4. <https://pubmed.ncbi.nlm.nih.gov/40906970/>

C/S80405 Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG and real-world data. Karam Ashouri, Joshua Millstein, Yan Yang, Joanne Xiu, Shivani Soni, Pooja Mittal, Sandra Algaze, Lesly Torres-Gonzalez, Priya Jayachandran, Wu Zhang, Shannon Mumenthaler, Anthony F Shields, Richard Goldberg, Emil Lou, Benjamin A Weinberg, Thomas G Graeber, John L Marshall, Alan P Venook, Alexander Hoffmann, Stacey D Finley, Aaron S Meyer, Francesca Battaglin, Heinz-Josef Lenz. *J Immunother Cancer*. 2025 Dec 21;13(12):e013186. doi: 10.1136/jitc-2025-013186. <https://pubmed.ncbi.nlm.nih.gov/41423272/>

C/S80702 Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance). En Cheng, Qian Shi, Anthony F Shields, Xiaonan Xue, Thomas E Rohan, Chaoyuan Kuang, Ardaman P Shergill, Chao Ma, Felix Couture, J Philip Kuebler, Pankaj Kumar, Benjamin Tan, Smitha S Krishnamurthi, Kimmie Ng, Eileen M O'Reilly, Justin C Brown, Jeffrey A Meyerhardt. *J Natl Cancer Inst*. 2025 Dec 1;117(12):2643-2652. doi: 10.1093/jnci/djaf281. NIHMS2114152. <https://pubmed.ncbi.nlm.nih.gov/40996326/>

C/S80702 Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. George Q Zhang, Jeffrey A Meyerhardt, Qian Shi, Tyler Twombly, Levi Pederson, Chao Ma, Juha P Väyrynen, Melissa Zhao, Yasutoshi Takashima, Ardaman Shergill, Pankaj Kumar, Felix Couture, Philip Kuebler, Smitha Krishnamurthi, Benjamin Tan, Eileen M O'Reilly, Marios Giannakis, Shuji Ogino, Adham Jurdi, Shruti Sharma, Alexey Aleshin, Anthony F Shields, Jonathan A Nowak. *JAMA Oncol*. 2025 Dec 4:e255144. doi: 10.1001/jamaoncol.2025.5144. Online ahead of print. NIHMS2113693. <https://pubmed.ncbi.nlm.nih.gov/41343176/>

E3201 Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201. Audrey E Kam, Fengmin Zhao, Neal J Meropol, Bruce J Giantonio, Robert B Diasio, Patrick J Flynn, Paul Catalano, Lee Hartner, Kendrith M Rowland, Wei Song, Mary F Mulcahy, Frank A Sinicrope, Robert P Whitehead, Robert J Mayer, Nicholas Petrelli, Peter J O'Dwyer,

Gastrointestinal Committee

Stanley R Hamilton, David Cella, Al B Benson. *Oncologist*. 2025 Dec 27;31(1):oyaf416. doi: 10.1093/oncolo/oyaf416.
<https://pubmed.ncbi.nlm.nih.gov/41397917/>

Submitted Manuscripts

C80702 Prognosis-Informed Phenotype Assignment: A Novel In-Situ Single-Cell Analysis Method for Phenotype Discovery. Lau M, Vayrynen J, Haruki K, Ma C, Vayrynen S, Ugai T, Gu S, Borowsky J, Zhao M, Arima K, Dias Costa A, Shields A, Innocenti F, KitTan W, Shi Q, Giannakis M, Fuchs C, Yu K, Nowak J, Ogino S. Submitted 2025.

NRG-GI004/S1610 Randomized Phase III Study of mFOLFOX/Bevacizumab/Atezolizumab or Atezolizumab alone as First-line Treatment of Deficient DNA-Mismatch Repair Metastatic Colorectal Cancer. Caio Max Sao Pedro Rocha Lima, Greg Yothers, Thomas J. George, Howard S. Hochster, Hanna K. Sanoff, Deirdre J. Cohen, Katherine A. Guthrie, Samuel A. Jacobs, Anwaar Saeed, Scott Kopetz, Linda H. Colangelo, Tanner J. Freeman, Scott W. Cole, Maged Khalil, Swapna Devanna, Dan S. Zuckerman, Theodore S. Hong, N. Lynn Henry, Patricia A. Ganz, Charles D. Blanke, Norman Wolmark, Michael J. Overman. Submitted 2026. [see also Symptom Management & Survivorship Committee]

Multiple Studies Disparities in SWOG GI Clinical Trial Enrollment. Safyan R, Colby S, Figueroa Moseley C, Guthrie K, Pumpalova Y, Hershman D, Chiorean E, Philip P. Submitted, 2025.

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1922	S2001	S2104	S2107	S2303	A021806	A022001
Banner University Medical Center - Tucson	-	-	11	-	-	1	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	2	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	-	-
Boston Medical Center	-	-	-	-	-	1	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	2	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	2	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	1	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	1	2	2	-	-	-
Cedars-Sinai Medical Center	-	-	1	-	2	-	-
City of Hope Comprehensive Cancer Center	-	6	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	1	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	2	3	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	2	-	-	2	-
Gulf South Minority Underserved NCORP	-	-	-	3	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	1	-	-
Heartland Cancer Research NCORP	1	1	-	3	-	-	-
Henry Ford Hospital	-	4	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	1	-	-	6	4	1	-
Loma Linda University Medical Center	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	1	-	-	-	-
Michigan Cancer Research Consortium NCORP	2	2	-	4	4	-	-
Moffitt Cancer Center	-	-	2	-	-	-	-
Montana Cancer Consortium NCORP	-	-	1	-	1	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	1	-
Northwestern University LAPS	1	-	1	-	1	1	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-
Oregon Health and Science University	-	-	3	-	4	5	-

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1922	S2001	S2104	S2107	S2303	A021806	A022001
Pacific Cancer Research Consortium NCORP	1	2	5	2	1	-	-
Regents of the University of Michigan	4	3	2	-	-	4	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	2	4	4	-	-	-
Sutter Cancer Research Consortium	-	1	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	2	-
The West Clinic - Wolf River	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	2	-	4	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	1	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	5	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	1	-	3	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	1	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	1	-	-	-	-
University of Colorado Cancer Center LAPS	-	4	-	9	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	1	-	-
University of Kentucky/Markey Cancer Center	-	-	4	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	1	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	2	-	-	-
University of Rochester LAPS	1	-	-	-	2	12	-
University of Texas Health Science Center at San Antonio	-	-	-	-	-	3	-
University of Texas MD Anderson Cancer Center LAPS	15	-	-	10	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	7	-	2	-	1
Vanderbilt University - Ingram Cancer Center LAPS	-	5	-	1	1	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	1	1	-	-	-
Yale University - Yale Cancer Center LAPS	-	1	2	-	2	2	1
ALLIANCE	12	8	12	8	26	-	-
ECOG-ACRIN	3	16	11	14	6	-	-
NRG	3	9	8	10	4	-	-
Total	45	73	86	88	74	37	2

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A022101	A022102	A022104	CCTG032	CCTGNE1	EA2174	EA2176
Banner University Medical Center - Tucson	-	-	-	-	1	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	13	-	-	-	-
Boston Medical Center	-	3	6	-	-	2	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	2	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	2	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	9	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	5	-	-	-	1
Houston Methodist Hospital	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	8
Loma Linda University Medical Center	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	1	-
Northwestern University LAPS	-	-	-	-	-	-	1
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	3	-	-
Oregon Health and Science University	-	-	-	1	-	-	4

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	A022101	A022102	A022104	CCTG032	CCTGNE1	EA2174	EA2176
Pacific Cancer Research Consortium NCORP	-	-	-	2	-	-	-
Regents of the University of Michigan	-	-	1	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	1	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	1	-	-	-	-
The West Clinic - Wolf River	-	-	17	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	4	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	7	5	3	-	-	4
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	1	1	-	-	1	3
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	1	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	2
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	1
University of Colorado Cancer Center LAPS	-	-	-	-	2	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	8	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-
University of Nebraska Medical Center	-	1	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-
University of Rochester LAPS	-	8	23	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	8	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	10
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	9	-	-	-	-
Virginia Mason Medical Center	-	-	8	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	6	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-
Total	1	36	110	8	6	6	34

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EA2182	EA2192	EA2197	EA2222	NRGG1004	NRGG1006	NRGG1008
Banner University Medical Center - Tucson	-	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	2
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	-	1
Boston Medical Center	2	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	4	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	1
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	5
Gulf South Minority Underserved NCORP	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-
Henry Ford Hospital	2	-	-	-	-	-	1
Houston Methodist Hospital	-	-	-	-	1	-	-
Intermountain Medical Center	-	-	-	-	-	-	2
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	1
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	1
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	1	-	-	-	1
Northwestern University LAPS	-	-	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
Oregon Health and Science University	1	4	6	2	-	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EA2182	EA2192	EA2197	EA2222	NRGG1004	NRGG1006	NRGG1008
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-
Regents of the University of Michigan	-	-	-	1	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	-	-	-	-	1
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	2	-	-	-	-	2
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	5
UC Davis Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	1	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	1	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	2	-	-	-	-	-	8
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	3	-	-	-
University of Nebraska Medical Center	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	1	1
University of Rochester LAPS	-	-	-	-	1	-	15
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	13	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	3
Virginia Mason Medical Center	-	-	1	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-
Total	14	6	9	6	15	1	50

